English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/60197
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

European perspective on multiple myeloma treatment strategies: Update following recent congresses

AuthorsLudwig, Heinz; Bladé, Joan; Cavo, Michele; Moreau, Philippe; San Miguel, Jesús F. ; Palumbo, Antonio
Issue Date2012
PublisherAlphaMed Press
CitationOncologist 17(5): 592-606 (2012)
AbstractThe management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies. ©AlphaMed Press.
Descriptionet al.
URIhttp://hdl.handle.net/10261/60197
DOI10.1634/theoncologist.2011-0391
Identifiersissn: 1083-7159
e-issn: 1549-490X
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.